Twin Malignancy of Acute Myeloid Leukemia and Multiple Myeloma in a Chemotherapy-Naïve Patient: A Rare Occurrence

Iffat Jamal1 Shuchismita1 Vijayanand Choudhary1

1 Department of Hematology, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India

J Lab Physicians

Address for correspondence: Shuchismita, MBBS, MD, Department of Hematology, Indira Gandhi Institute of Medical Sciences, Patna, 800014, Bihar, India (e-mail: shuchi.smita123@gmail.com).

Abstract

Synchronous diagnosis of acute myeloid leukemia (AML) and multiple myeloma in chemotherapy-naïve patients is a rare event and poses a serious therapeutic challenge as it imparts a poor prognosis. We report a case of concurrent AML with multiple myeloma in a 44-year-old male along with a PubMed-based research of previously reported similar cases in published literature.

Introduction

Multiple myeloma (MM) and acute myeloid leukemia (AML) may usually develop in the same patient but they are generally seen in MM patients receiving chemotherapy and in due course of treatment AML develops. However, simultaneous occurrence of MM and acute leukemia on presentation in chemotherapy-naïve patients is rare, with only a 25 cases reported in the literature so far.2 3 Herein, we are reporting such a case of dual malignancies in a 44-year-old male who was not exposed to any chemotherapy or radiotherapy prior to presentation.

Case Report

A 44-year-old male patient presented with severe generalized weakness, fever, persistent dry cough, and low back pain for 2 months. He had also a past history of repeated blood transfusions for prolonged anemia and generalized weakness. There was no prior history of any long-term medications.

On clinical examination, pallor was present. Abdomen palpation revealed moderate hepatosplenomegaly. Liver function tests showed reverse A:G ratio. Kidney function tests showed increased blood urea and serum creatinine levels.

Complete blood count revealed hemoglobin – 6.2 gm/dL and white blood cell count of 44,000/cumm with the presence of 94% blasts, few demonstrating Auer rods. Platelet count was reduced (53,000/cumm; Fig. 1A) Bone marrow aspiration was performed that was hypercellular for age with diffuse infiltration by blasts leading to marked suppression of trilineage hematopoiesis with increased plasma cells (10%; Fig. 1B). Bone marrow biopsy (done using Hammer smith protocol) revealed presence of few plasma cells that were positive for CD38, CD138, and kappa con (Fig. 1C and D). Due to deranged renal function tests, serum protein electrophoresis was ordered that shows presence of M spike (2.2 g/dL) in

Keywords

► acute myeloid leukemia
► chemotherapy
► multiple myeloma
► naïve
► simultaneous

ISSN 0974-2727.

© 2022. The Indian Association of Laboratory Physicians. All rights reserved.
This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd., A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
Twin Malignancy of AML and MM in a Chemotherapy-Naïve Patient

Discussion

The association of AML with MM is seen as a complication of chemotherapy, but it may also occur in the absence of this treatment. This synchronous occurrence of AML and MM in the same patient without previous exposure to chemotherapy is a very rare event. About 5 to 10% of AML cases are seen associated with plasmacytosis; thus, it is extremely important to rule out its neoplastic nature by carrying out MM workup.

Secondly, none of the hematological malignancies should be therapy related to fulfill the criteria for the twin diagnosis of AML and MM. Several pathophysiological mechanisms have been proposed to explain the simultaneous occurrence of these two malignancies. These include a disorder of multipotent stem cells exposure to common environmental risk factors and repeated infections in a patient of MM, which might result in the development of a leukemic clone. Another explanation may be that MM is a slowly evolving disease with a resultant decrease in immune surveillance and incipient leukemic clones might escape this immune surveillance concurrently.

A PUBMED database search was made for synchronous occurrence of AML with MM from 1970 to 2021 and data was analyzed. Herein, we reported a case of simultaneous occurrence of AML and MM in a patient without previous exposure to chemotherapy. There is a possibility that these two malignancies may originate from common stem cells but it has not been supported with adequate evidence.

Malhotra et al reported 15 cases diagnosed with both Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) and MGUS or MM at their institute over a period of 5 years. Eleven patients with monoclonal gammopathy of undetermined significance (MGUS) and two patients with MM had received prior radiation treatment or chemotherapy and then developed MPNs. The two other patients with MM who did not receive any cytotoxic treatment developed myelofibrosis.

Multiple gene mutations and deletions of RB-1, TP53, and IP32 and some susceptible genes may be involved in the simultaneous occurrence of both malignancies. But the exact mechanism leading to the simultaneous occurrence of AML and MM is still debatable.

After technological advancements in diagnostic modalities and with the introduction of newer principles of flowcytometry, fluorescence in situ hybridization (FISH), and karyotyping, genetic and molecular biomarkers have been discovered that play a key role in simultaneous occurrence of AML and MM.

Before 2003, all case reports of simultaneous presentation of AML and MM performed a type of serum immunofixation test that revealed the types of paraproteins in patients, including IgA, IgA/k, IgG, IgG/k, and IgG/λ; however, few cases conducted the chromosome type test, and the results displayed 46XY and hypodiploidy, as well as chromosomal abnormalities.

Luca and Almanaseer in 2003 performed flowcytometry and demonstrated presence of myeloblasts with positive...
Fig. 3 (A–C) Immunophenotyping showing positivity for CD 45, cytoplasmic myeloperoxidase (MPO), CD117, CD13, and CD33. (D–E) Immunophenotyping revealing CD34, Tdt, and CD22-negative blast population.

Table 1  Comparative study of PUBMED database for synchronous occurrence of AML with MM

<table>
<thead>
<tr>
<th>Name of the study and year</th>
<th>Age (years)</th>
<th>Sex (M/F)</th>
<th>Subtype of AML (FAB)</th>
<th>Type of paraprotein</th>
<th>Karyotype</th>
<th>Survival from diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thijs et al (1970)¹</td>
<td>47</td>
<td>F</td>
<td>AML</td>
<td>IgA/κ</td>
<td>ND</td>
<td>4 months</td>
</tr>
<tr>
<td>Taddelnl and Schrader (1972)²</td>
<td>73</td>
<td>M</td>
<td>AMMoL</td>
<td>IgG/λ</td>
<td>ND</td>
<td>6 months</td>
</tr>
<tr>
<td>Parker (1973)⁶</td>
<td>79</td>
<td>M</td>
<td>AMMoL</td>
<td>Normal</td>
<td>ND</td>
<td>Few weeks</td>
</tr>
<tr>
<td>Tursz et al (1974)⁷</td>
<td>77</td>
<td>M</td>
<td>AML</td>
<td>IgA/κ</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Rosner and Grünwald (1974)⁸</td>
<td>79</td>
<td>M</td>
<td>AMMoL</td>
<td>ND</td>
<td>ND</td>
<td>Died shortly after diagnosis</td>
</tr>
<tr>
<td>Cleary et al (1978)⁹</td>
<td>64</td>
<td>M</td>
<td>AMMoL</td>
<td>IgA/κ</td>
<td>Normal</td>
<td>4–5 months</td>
</tr>
<tr>
<td>Thiagrajan (1979)¹¹</td>
<td>72</td>
<td>M</td>
<td>AML</td>
<td>IgA/κ</td>
<td>Aneuploidy</td>
<td>5 months</td>
</tr>
<tr>
<td>Kastanas et al (1979)¹⁰</td>
<td>70</td>
<td>M</td>
<td>ND</td>
<td>IgG</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Vallantin et al (1980)¹¹</td>
<td>69</td>
<td>M</td>
<td>AML</td>
<td>IgG/λ</td>
<td>ND</td>
<td>Few weeks</td>
</tr>
<tr>
<td>Annino et al (1980)¹²</td>
<td>74</td>
<td>M</td>
<td>AMMoL</td>
<td>IgG/κ</td>
<td>Hypodiploidy; t (8;13)</td>
<td>2 months</td>
</tr>
<tr>
<td>Parapia et al (1982)¹</td>
<td>79</td>
<td>M</td>
<td>AMMoL</td>
<td>IgG/λ</td>
<td>Normal</td>
<td>5 weeks</td>
</tr>
<tr>
<td>Naparstek et al (1982)¹³</td>
<td>68</td>
<td>M</td>
<td>AMoL</td>
<td>IgG/κ</td>
<td>ND</td>
<td>15 months</td>
</tr>
<tr>
<td>Raz and Polliack (1984)¹⁴</td>
<td>68</td>
<td>M</td>
<td>AMoL</td>
<td>IgG/κ</td>
<td>Normal</td>
<td>2.5 years</td>
</tr>
<tr>
<td>Kumar et al (2016)¹⁵</td>
<td>73</td>
<td>M</td>
<td>AML</td>
<td>IgG</td>
<td>ND</td>
<td>4 months</td>
</tr>
<tr>
<td>Dash et al (1991)¹⁶</td>
<td>32</td>
<td>M</td>
<td>AML</td>
<td>IgG/λ</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Thomas et al (2012)¹⁷</td>
<td>73</td>
<td>M</td>
<td>AMoL</td>
<td>IgG/κ</td>
<td>ND</td>
<td>12 months</td>
</tr>
<tr>
<td>Thomas et al (2012)¹⁷</td>
<td>70</td>
<td>M</td>
<td>AML</td>
<td>IgG/κ</td>
<td>ND</td>
<td>4 months</td>
</tr>
<tr>
<td>Anderson et al (1999)¹⁸</td>
<td>51</td>
<td>M</td>
<td>AML</td>
<td>κ</td>
<td>ND</td>
<td>2 months</td>
</tr>
</tbody>
</table>

(Continued)
expression of Cd14, CD33, and HLA-DR, and a negative expression of CD45 for plasma cells with cytogenetics revealing Monosomy. Kim et al reported a case of simultaneous presentation of AML and MM with k-type paraprotein with immunohistochemical test showing plasma cells to be positive for CD138 with kappa light chain restriction and myeloblasts to be positive for CD34 and CD117. Flow cytometry confirmed the presence of two distinct neoplastic populations of plasma cells and myeloblasts. FISH revealed a complex chromosomal pattern, with +5, +7, +8, +8q22, +11q23, −13q14, −16q22, +17q13.1, +20q12, and +21q22, and immunoglobulin heavy chain rearrangement.

Prognosis remains extremely poor with no standard treatment established because of its rare occurrence. Patients are often treated with therapy for AML since AML is more aggressive, and anthracycline group of drugs seems to be effective against MM as well. Raz and Polliack described a 68-year-old man developing simultaneously with AML and MM and he was treated with a combination of vincristine, cyclophosphamide, melphalan, and prednisolone. This resulted in disappearance of monoblasts with decreased serum paraprotein level. Kim et al described a 51-year-old man who was concurrently diagnosed with AML and MM and treated with cytarabine and idarubicin along with bortezomib, followed by reinduction with mitoxantrone and high-dose cytarabine. But there was incomplete induction response and subsequently he underwent allogenic stem cell transplantation.

Recently drugs like tipifarnib and bortezomib together have been shown to be synergistic in AML and MM cell lines, but usefulness of such therapies still needs a thorough evaluation.

Table 1 (Continued)

<table>
<thead>
<tr>
<th>Name of the study and year</th>
<th>Age (years)</th>
<th>Sex (M/F)</th>
<th>Subtype of AML (FAB)</th>
<th>Type of paraprotein</th>
<th>Karyotype</th>
<th>Survival from diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luca and Almanaseer (2003)9</td>
<td>77</td>
<td>M</td>
<td>AMoL</td>
<td>IgG/κ</td>
<td>Monosomy 13; deletion of 20q</td>
<td>1 month</td>
</tr>
<tr>
<td>Yanagimoto et al (2003)20</td>
<td>82</td>
<td>F</td>
<td>AML</td>
<td>λ</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Attili et al (2006)5</td>
<td>57</td>
<td>F</td>
<td>AML</td>
<td>IgG/κ</td>
<td>46 XY;7q(8;21)</td>
<td>ND</td>
</tr>
<tr>
<td>Shukla (2008)21</td>
<td>58</td>
<td>F</td>
<td>AML</td>
<td>IgG/λ</td>
<td>ND</td>
<td>1 month</td>
</tr>
<tr>
<td>Kim et al (2010)22</td>
<td>51</td>
<td>M</td>
<td>AML</td>
<td>κ</td>
<td>Complex</td>
<td>11 months</td>
</tr>
<tr>
<td>Murukutla et al (2014)23</td>
<td>66</td>
<td>F</td>
<td>AML-M5</td>
<td>κ</td>
<td>ND</td>
<td>4 weeks</td>
</tr>
<tr>
<td>Lu-Qun et al (2015)24</td>
<td>73</td>
<td>M</td>
<td>AML</td>
<td>IgA/λ</td>
<td>ND</td>
<td>6 months</td>
</tr>
<tr>
<td>Sashida et al (2003)26</td>
<td>55</td>
<td>F</td>
<td>AML-M1</td>
<td>IgG/κ</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Mailankody et al (2011)27</td>
<td>73</td>
<td>F</td>
<td>AML post MDS 5q</td>
<td>IgG</td>
<td>ND</td>
<td>12 months</td>
</tr>
<tr>
<td>Present case (2021)</td>
<td>68</td>
<td>M</td>
<td>AML</td>
<td>M spike -beta-2 globulin with kappa restriction</td>
<td>ND</td>
<td>Alive after 2 months of start of treatment</td>
</tr>
</tbody>
</table>

Abbreviations: AML, acute myeloid leukemia; AML-M1, acute myeloid leukemia without maturation; AMoL, acute myelomonocytic leukemia; AMoL, acute monocytic leukemia; FAB, French-American-British; IgA, immunoglobulin A; IgG, immunoglobulin G; ND, not defined.

Conclusion

Synchronous presence of AML with MM in a chemotherapy-naïve patient is an extremely rare occurrence. Concurrent diagnosis of these two hematological malignancies yields a poor prognosis and a proper treatment plan is still awaited.

Funding
None.

Conflict of Interest
None declared.

References


